SCHEMBL142033

SCHEMBL142033

CC(=O)c1cccc2c1C(=O)c1c(O)cccc1C2=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.69
MAPT P10636 4/20 0.69
TDP1 Q9NUW8 4/20 0.69
TSHR P16473 3/20 0.69
MAOA P21397 3/20 0.69
MAPK1 P28482 3/20 0.69
HPGD P15428 3/20 0.69
ALOX15 P16050 3/20 0.69
SMN1; SMN2 Q16637 3/20 0.69
HSD17B10 Q99714 3/20 0.69
LMNA P02545 2/20 0.69
MAOB P27338 2/20 0.69
HTT P42858 1/20 0.69
FTO Q9C0B1 2/20 0.58
ELANE P08246 5/20 0.57
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
CTSG P08311 4/20 0.57
KDM4E B2RXH2 3/20 0.57
CYP3A4 P08684 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29366938 0.95 MAOA (0.68) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL140425 0.95 MAOA (0.68) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL30361371 0.95 MAOA (0.68) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL8505898 0.91 ALDH1A1 (0.58) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL23723959 0.84 FTO (0.73) ALDH1A1MAPTTDP1TSHRMAOA
SCHEMBL11147739 0.84 ALDH1A1 (0.70) ALDH1A1MAPTTDP1MAOAMAPK1
Danthron SCHEMBL28137084 0.83 MAPT (0.91) ALDH1A1MAPTTDP1TSHRMAOA
Danthron SCHEMBL30544826 0.83 MAPT (1.00) ALDH1A1MAPTTDP1TSHRMAOA
Danthron SCHEMBL29356886 0.83 MAPT (1.00) ALDH1A1MAPTTDP1TSHRMAOA
Danthron SCHEMBL83688 0.83 MAPT (1.00) ALDH1A1MAPTTDP1TSHRMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120059067-A1 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE CHARLESSON, LLC (US) 2012-03-08 US disclosed
US-20120059067-A1 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE CHARLESSON, LLC (US) 2012-03-08 US disclosed
US-8058316-B2 STAT3 inhibiting compositions and methods CHARLESSON, LLC (US) 2011-11-15 US disclosed
US-8058316-B2 STAT3 inhibiting compositions and methods CHARLESSON, LLC (US) 2011-11-15 US disclosed
US-20110077306-A1 STAT3 INHIBITING COMPOSITIONS AND METHODS CHARLESSON, LLC (US) 2011-03-31 US disclosed
US-20110077306-A1 STAT3 INHIBITING COMPOSITIONS AND METHODS CHARLESSON, LLC (US) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077306-A1 STAT3 INHIBITING COMPOSITIONS AND METHODS STAT3, STAT1, STAT5B ALDH1A1 1563/4885MAPT 669/4885TDP1 3879/4885
US-20120059067-A1 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE ACAT1, ACAT2, LCLAT1 ALDH1A1 55/4885MAPT 65/4885TDP1 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.